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Association between age and the initiation of antihypertensive, lipid lowering and antiplateletet medications in elderly individuals newly treated with antidiabetic drugs SIR-The elderly are the age group most affected by diabetes mellitus [1] . Given that the general population is ageing, the number of older individuals with diabetes is likely to increase. Moreover, diabetes is often accompanied by several co-morbidities [2] , not to mention cardiovascular disease (CVD), the main complication of diabetes [3] .
Antihypertensive [4] , lipid-lowering [5] and antiplatelet [6] drugs are known to decrease cardiovascular complications in diabetes. Even though there is little evidence from clinical trials in elderly patients with diabetes, most older patients with this condition require pharmacological treatments in order to reach the clinical targets recommended in guidelines [7] [8] [9] . The Canadian Diabetes Association recommends the same targets for older patients than for younger ones (130/ 80 mmHg; LDL-cholesterol 2.6 mmol/l), although more conservative objectives are suggested for individuals with multiple co-morbidities [7] . Similar recommendations are found in guidelines from other associations [8, 9] .
In many instances, there is evidence that quality of treatment diminishes with increasing age [10] [11] [12] [13] [14] . In a study of 6,626 prevalent users of antidiabetic drugs, the older the individuals were, the less likely they were to use a statin or an angiotensin converting enzyme (ACE) inhibitors [10] . However, since patients could have been using cardiovascular protective treatments before they started oral antidiabetic drugs, the question remains as to whether or not age affects initiation of cardioprotective treatments among individuals with diabetes.
The objective of this study was to assess the association between age and the initiation of antihypertensive, lipidlowering and antiplatelet drugs during the year following commencement of an oral antidiabetic drug among individuals aged 66 years and over.
Methods
We performed a population-based cohort study using the Quebec Diabetes Surveillance Database (QDSD). The database results from the linking of five public health administrative databases. For individuals who had been diagnosed with diabetes, it includes information on patient demographics, physician and hospital services and data from the public drug plan.
From the QDSD, individuals aged ≥66 years were selected if they had initiated an oral antidiabetic drug between 1 January 1998 and 31 December 2002. The date of the first claim formed the index date. We excluded all individuals who (1) had a claim for insulin or any oral antidiabetic drug in the year before the index date, (2) had not been beneficiaries of the provincial prescription drug insurance plan for the entire year before the index date and (3) did not have at least one year of follow-up.
From the remaining patients, three sub-cohorts were identified: the antihypertensive drug-free, the antiplatelet drug-free and the lipid-lowering drug-free sub-cohorts. The sub-cohorts were made up of patients with respectively no claim for any antihypertensive, antiplatelet and lipid-lowering drug during the year before the index date.
The outcome variable for the antihypertensive drug-free sub-cohort was defined as a prescription for an antihypertensive drug in the year following the index date: likewise an antiplatelet drug for the antiplatelet drug-free sub-cohort, and similarly, a lipid-lowering drug in the lipid-lowering drug-free sub-cohort.
The proportion of individuals initiating therapy according to four age groups (66-70, 71-75, 76-80 and ≥81 years) in each sub-cohort was calculated. A trend analysis was done using the Mantel-Hanszel chi-square test (α = 0.05). We computed adjusted odds ratios (OR) with 95% confidence intervals (CI) of initiating an antihypertensive, antiplatelet or lipid-lowering drug treatment according to the age groups. Analyses were performed using SAS, version 9.1 (SAS Institute, Inc., Cary, NC, USA). Access to the data used in this research was authorized by the Commission d'accèsà l'information du Québec.
Results
During the study period, a total of 48,505 individuals who initiated an oral antidiabetic drug treatment fitted the inclusion criteria. Their characteristics are presented in Table 1 . Among the individuals included in the antihypertensive drugfree sub-cohort (n = 15,290 (32%)), the risk of initiating an antihypertensive drug treatment in the year following the index date decreased with age (P for trend <0.001). Similarly, the risk of initiating an antiplatelet or a lipidlowering drug treatment decreased as age increased in the antiplatelet drug-free (P = 0.119) and lipid-lowering drugfree (P < 0.001) sub-cohorts respectively, although the trend was not statistically significant in the antiplatelet drug-free group (Table 2) . a Adjusted odds ratios (AOR): adjusted for sex, area of residence (metropolitan: urban core of at least 100,000 people and its adjacent municipalities; agglomeration: urban core of at least 10,000 people but <100,000 and its adjacent municipalities; rural: municipalities not included in the former two categories), calendar year of oral antidiabetic drug initiation, and for the following variables measured in the year prior to index date: hospitalization, number of outpatient physician consultations, number of different drugs used, and cardiovascular disease.
Discussion
Among elderly who started an oral antidiabetic drug, age had an influence on whether or not they were exposed in the following year to a cardioprotective drug that they had not been using before.
Other studies have shown that older age is associated with underuse of evidence-based therapies. In a study of patients with atrial fibrillation, warfarin use decreased with each advancing decade of life, independently of other risk factors and bleeding contraindications [13] . In another study, older patients experienced a decreased probability of receiving thrombolysis for acute myocardial infarction [14] . Lastly, Glynn et al. [11] reported that the likelihood of being exposed to insulin or to oral antidiabetic drugs decreased with increasing age after hospital discharge. However, the question of whether the lower use of evidence-based treatments among older patients reflected appropriate clinical judgment or an inappropriate care gap is difficult to answer [14] . We propose seven hypotheses that could explain the lower odds of initiating cardioprotective drug treatments among the oldest individuals in the cohort.
First, individuals who need oral antidiabetics at older age and who were not treated before for cardiovascular risk factors may be healthier. However, in a study of 1,375 patients aged 50-74 years with prevalent diabetes, there was no evidence of a decrease in the prevalence of systemic hypertension or dyslipidaemia among the older age groups [15] .
Second, the 'older older' individuals may have more comorbidities and contraindications for drug treatments than the 'younger older'. As the databases do not capture clinical data, it was not possible to take all co-morbidities into account in the analysis.
Third, some physicians may be reluctant to prescribe additional drugs to older patients as the risk of interactions and side-effects is likely to increase [16] . Nonetheless, it has been reported that elderly patients with high cardiovascular risks are often denied statins without there being any meaningful basis for the decision [17] . Many older patients with diabetes would therefore benefit from a thorough examination of the risks and benefits of cardioprotective therapies.
Fourth, one might argue that the elderly with frailty or limited life expectancy should not be prescribed protective treatments. Frailty [18] is difficult to assess using administrative data. Also, there were patients whose life expectancy was not long enough to anticipate benefits from long-term therapy and they were not excluded from our study because they survived longer than a year after the index date.
Fifth, cost of therapy may be prohibitive. However, since many elderly with diabetes reach their cap on the monthly contribution required under the drug plan, the prescription of cardioprotective drugs would not necessarily add to a patient's financial burden in Quebec.
Sixth, there is a lack of clear evidence supporting the clinical benefit of antiplatelet [19] and lipid-lowering therapies in the older patient with diabetes [20] . This could explain partly why the proportion of those who acquired these drugs was low. Nevertheless, considering that the benefits of antihypertensive treatment is well established [21] and that almost all older patients with diabetes would qualify for ACE inhibitors or angiotensin receptor blocker therapy [22] , it might be expected that the proportion of individuals newly treated for diabetes who later initiated antihypertensive drugs would be higher than what was observed.
Lastly, the seventh hypothesis concerns a latent will to avoid 'aggressive' treatment of older individuals as they are ageing. However, as more aggressive clinical interventions such as revascularizations are carried out in older patients with cardiovascular disease [23, 24] , it would be unethical not to offer the same level of pharmacological treatment protection, should this pharmacological treatment prove appropriate.
This study has some limitations. First, there is yet no clear evidence that all cardioprotective drugs are of benefit in the elderly population with diabetes. Our assumptions are based upon recommendations from clinical guidelines, which are based on data from clinical trials performed in younger individuals. Similarly, since the database does not capture clinical data, it was not possible to assess appropriateness of drug treatments or contraindications. Next, because acetylsalicylic acid can be purchased without prescription, it may have underestimated the proportion of individuals taking antiplatelet drugs. Lastly, analysed data were for the years 1998 to 2003; the situation may have changed since. The recently established evidence of benefits of antihypertensive therapy among the very old [25] may increase future use of these agents. Similarly, an increased use of lipid-lowering drugs may, however, have occurred after 2003 as clinical studies [5, 26] suggested that even the oldest patients benefited from the use of statins, although this might not apply to the very old (>85 years).
In conclusion, we observed an age-related gap between the guidelines and clinical practice that may come about from physiologically or medically driven decisions or from unwillingness to treat because of older age. Future research is needed to address these issues more specifically. There is also a need for clinical studies to examine the efficacy of cardioprotective treatments in the older patient with diabetes. Indeed, evaluating the quality of the care process (the use of cardioprotective treatments) is irrelevant if it does not translate into clinical benefits.
Key points
r Antihypertensive, antiplatelet and lipid-lowering drugs are recommended to reduce cardiovascular complications in elderly with diabetes, but whether or not age affects initiation of cardioprotective treatments remains unknown. r Our results suggest that exposure to cardioprotective drugs in the year following oral antidiabetic therapy initiation is indeed associated with the patient's age. r The age-related gap between the recommendations and clinical practice may come about from physiologically or medically driven decisions or from unwillingness to treat because of older age.
Gait variability in younger and older adult women is altered by overground walking protocol
SIR-Measures of gait variability are now commonly used to study age-related gait changes [1] [2] [3] [4] [5] [6] [7] . Some studies have shown that older adult fallers, and those identified with an increased falls risk, exhibit greater variability in basic spatiotemporal measures of gait when compared to both older adult non-fallers [2, 4, 5] and younger adults [4] . However, other work has reported no differences in measures of gait variability between healthy younger and older adults [6] , healthy and frail older adults [7] and older adult fallers and non-fallers [1, 3] .
A possible reason for the ambiguous findings of the previous studies may lie in the different walking protocols used to collect the gait data. Studies that have reported no effect of age on measures of gait variability commonly used repeated single over-ground walking protocols [1, 3, 6, 7] . Conversely, studies using continuous over-ground walking protocols have reported significant age effects [2, 4, 5, 8] . Repeated single trial walking protocols generally involve repetitive periods of waiting, gait initiation in response to an auditory command, steady-state walking for several strides, followed by gait termination at the end of a short walkway. In contrast, continuous walking protocols typically involve walking without interruption over longer distances. It is possible that the frequent disruptions to the temporal locomotor rhythm of gait experienced during repeated single walking protocols may affect gait variability and thereby contribute to the ambiguous findings reported by gait variability studies [9] .
To our knowledge, no study has investigated the effect of repeated single and continuous over-ground walking protocols upon measures of gait variability. As such, little is known about the effect of these protocols upon measures commonly used to investigate gait changes associated with ageing. The aim of this study therefore was to determine whether gait variability data captured during repeated single over-ground walking differs from variability data captured during continuous over-ground walking in younger and older women.
Methods

Participants
Twenty-two younger female volunteers (age: 21.2 ± 2.5 years, height: 1.66 ±0.08 m; mass: 62.6 ± 9.8 kg) and 32 older female volunteers (age 67.4 ± 6.3 years, height: 1.62 ± 0.07 m; mass: 65.1 ± 13.2 kg) participated in this study. The older adults were recruited through advertisements distributed to local senior social groups, whereas the younger adults were recruited through advertisements placed on University notice boards. The Human Research Ethics Committee at Australian Catholic University approved all procedures for this study.
Volunteers wore comfortable clothing and walking shoes with a heel height <2.5 cm. On arrival, participants were screened using a previously published protocol [10] to ensure that they did not have any overt health problems impacting on balance and mobility. Written informed consent was obtained prior to testing.
Procedure
Participants completed two walking protocols presented in random order. The first protocol involved ten repeated single walking trials and the second protocol involved ten continuous laps of a walking circuit. Ten trials/laps were performed to ensure that representative gait data were collected [11] . The repeated single walking protocol required participants to walk at self-selected speed along a flat walkway containing an 8.1 m instrumented GAITRite mat (CIR Systems Inc., Havertown, PA, USA). The participant was asked to start walking in response to a 'go' signal and stop at a designated finish position. The start and finish positions were indicated by markers placed two body lengths before and after the mat so as to ensure steady-state walking across the GAITRite [12] . After completing the trial, the participant waited at the finish position whilst the data was processed, and then walked back to the start position in response to a 'go' command for the next trial. Data were recorded for each traverse of the walkway.
The continuous walking protocol consisted of a curvilinear circuit that incorporated two straight sections (3 m apart) that were of the same length as the repeated single walking condition. The GAITRite mat was positioned along one of the straight sections. On a 'go' command, participants completed 10 laps of the circuit at self-selected speed. The GAITRite system was re-set when each participant was on the opposite side of the circuit. A treadmill was not used to collect continuous gait variability data as past work has shown that parameters such as stride time variability are altered by treadmill walking [9] .
